Omura, Junichi
Makanji, Yogeshwar
Tanabe, Nobuhiro
Yu, Dae Young
Tan, Jin Yu
Lim, Sooyeol
Kouhkamari, Mahsa H.
Casorso, Jeremy
Wu, David Bin-Chia
Bloomfield, Paul
Funding for this research was provided by:
Janssen Asia Pacific Medical Affairs
Article History
Received: 30 August 2023
Accepted: 6 November 2023
First Online: 22 November 2023
Declarations
:
: Junichi Omura is an employee of Janssen Pharmaceuticals. Yogeshwar Makanji is an employee of Janssen Pharmaceuticals. Nobuhiro Tanabe has nothing to disclose. Dae Young Yu is an employee of Janssen Pharmaceuticals. Jin Yu Tan is an employee of Janssen Pharmaceuticals. Sooyeol Lim is a former employee of Prospection, which received funding from Janssen to conduct the study analyses. Mahsa H. Kouhkamari is a former employee of Prospection, which received funding from Janssen to conduct the study analyses. Jeremy Casorso is a current employee of Prospection, which received funding from Janssen to conduct the study analyses. David Bin-Chia Wu is an employee of Janssen Pharmaceuticals. Paul Bloomfield was an employee of Janssen Pharmaceuticals at the time of the analysis.
: This study was implemented and reported in accordance with the International Conference on Harmonised (ICH) Tripartite Guidelines for Good Clinical Practice with applicable local regulations (including European Directive 2001/20/EC, US CFR 21 and Japanese Ministry of Health, Labor, and Welfare), and with the ethical principles laid down in the Declarations of Helsinki. On the basis of Ethical Guidelines for Epidemiological Research issued by the Japanese Ministry of Health, Labor and Welfare, ethics approval and informed consent are not applicable for this study. Reference: The Ministry of Education, Culture, Sports, Science and Technology, The Ministry of Health, Labour and Welfare. Ethical principles in research ethics and Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects [in Japanese]. ExternalRef removed. Accessed 3 February 2023.